Table I.
Clinical summaries of patients treated with tofacitinib
| Patient No./Age/sex | Disease duration | Clinical presentation | Previous treatments | Concurrent treatments | Duration of tofacitinib treatment | CLASI activity |
Clinical outcome | |
|---|---|---|---|---|---|---|---|---|
| Before | After | |||||||
| 1/50s/M | 2 years | Discoid lupus Raynaud syndrome and fingertip ulcerations | HCQ MTX MMF Prednisone |
MMF 2 g/d HCQ 400 mg/d 5/7 days and 200 mg/d 2/7 days Prednisone 5 mg/d |
4 months | 28∗ | 8∗ | Improvement in discoid lupus Ongoing Raynaud syndrome despite treatment |
| 2/70s/F | 8 years | SCLE Sjögren syndrome |
HCQ CQ Quinacrine CsA MMF Acitretin |
HCQ 200 mg/d | 7 months | 21∗ | 0∗ | Resolution of all cutaneous lesions of lupus |
| 3/50s/F | 11 years | Discoid lupus Tumid lupus ACLE SLE |
HCQ CQ Quinacrine MTX AZA MMF Prednisone |
Prednisone 10 mg/d | 1 month | 23 | 16 | Effectiveness on limbs but ongoing facial involvement, tofacitinib switched to MMF and prednisone 20 mg/d after 1 month |
ACLE, Acute cutaneous lupus erythematosus; AZA, azathioprine; CLASI, cutaneous lupus erythematosus disease area and severity index; CsA, cyclosporine; CQ, chloroquine; HCQ, hydroxychloroquine; MTX, methotrexate; MMF, mycophenolate mofetil; SCLE, subacute cutaneous lupus erythematosus; SLE, systemic lupus erythematosus.
∗
CLASI scores from patients 1 and 2 were calculated using patient-supplied pictures.